Profile data is unavailable for this security.
About the company
Laboratorio Reig Jofre SA, formerly Natraceutical SA, is a Spain-based company primarily engaged in the research, development, manufacturing and marketing of drugs. The Company’s activities are divided into four business divisions: Industrial Services, providing production services for third parties; Pharma, selling own pharmaceuticals under a range of brands, such as Reig Jofre, Medea, Orravan, Bioglan and Sala; Reaserch and Development (R&D) and Regulatory, including the development of indications for existing molecules, as well as generics and molecular diagnostics, among others; and Biotech, offering biopharmaceutical support services, such as analytical and process development, quality control and assurance, as well as stability studies. The Company also provides nutritional cosmetics, and food supplements, among others. It operates worldwide in Europe, Africa, the Americas, Australia and Asia through a number of subsidiaries, including Chiesi Espana SA and Oryzon Genomics SA.
- Revenue in EUR (TTM)327.87m
- Net income in EUR4.25m
- Incorporated--
- Employees1.42k
- LocationLaboratorio Reig Jofre SAGran Capita, 10SANT JOAN DESPI 08970SpainESP
- Phone+34 934806710
- Websitehttps://reigjofre.com/es/
Mergers & acquisitions
| Acquired company | RJF:MCE since announced | Transaction value |
|---|---|---|
| LeanBio SL | -3.72% | 4.06m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Euroapi SA | 882.80m | -124.30m | 205.14m | 3.43k | -- | 0.2143 | -- | 0.2324 | -1.31 | -1.31 | 9.33 | 10.01 | 0.5453 | 1.29 | 5.67 | 257,526.30 | -7.68 | -4.32 | -11.36 | -5.77 | 13.71 | 14.37 | -14.09 | -7.36 | 0.7994 | -1.65 | 0.0671 | -- | -9.79 | 0.0741 | 31.15 | -- | 5.71 | -- |
| Adimmune Corp | 32.39m | -13.71m | 208.47m | 564.00 | -- | 1.61 | -- | 6.44 | -1.21 | -1.21 | 2.85 | 11.21 | 0.1413 | 1.43 | 2.11 | -- | -7.07 | 0.5893 | -8.86 | 0.6742 | 2.67 | 32.30 | -50.05 | 2.71 | 1.42 | -49.73 | 0.4028 | 31.00 | -12.78 | 3.68 | 62.06 | -- | -15.71 | -- |
| Bliss GVS Pharma Ltd | 80.68m | 10.14m | 208.49m | 966.00 | 20.83 | -- | 15.24 | 2.58 | 10.18 | 10.18 | 80.97 | -- | -- | -- | -- | 8,986,598.00 | -- | 6.04 | -- | 7.54 | 52.65 | 46.33 | 13.18 | 9.45 | -- | 8.44 | -- | 8.27 | 5.13 | 3.27 | 11.72 | -2.82 | 5.18 | 0.00 |
| Coherus Oncology Inc | 70.74m | -158.69m | 211.29m | 161.00 | -- | 2.21 | -- | 2.99 | -1.62 | 1.33 | 0.721 | 0.7551 | 0.1636 | 1.76 | 0.9453 | 366,526.30 | -36.70 | -21.44 | -106.02 | -31.54 | 47.79 | 71.26 | -224.34 | -42.66 | 1.23 | -15.12 | 0.3656 | -- | 3.78 | -5.60 | 111.98 | -20.51 | -- | -- |
| Laboratorio Reig Jofre SA | 327.87m | 4.25m | 213.77m | 1.42k | 49.89 | 0.9753 | 10.98 | 0.652 | 0.0521 | 0.0521 | 4.04 | 2.67 | 0.9341 | 1.88 | 5.34 | 231,058.50 | 1.24 | 2.39 | 1.61 | 3.15 | 60.48 | 60.25 | 1.32 | 2.78 | 0.9907 | 4.94 | 0.2265 | -- | 7.22 | 11.10 | 10.36 | 16.00 | -7.77 | -- |
| Innovacell Inc | -542.40m | -542.40m | 215.96m | 48.00 | -- | 125.94 | -- | -- | -- | -- | -- | 7.58 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 12.78 | -- | 0.9377 | -- | -- | -- | -19.48 | -- | -- | -- |
| Qinghai Spring Medicinl Rsrcs Tech CoLTD | 35.15m | -13.72m | 217.37m | 159.00 | -- | 1.71 | -- | 6.18 | -0.1864 | -0.1864 | 0.496 | 1.75 | 0.2492 | 1.08 | 4.07 | 1,790,944.00 | -9.61 | -15.06 | -10.10 | -15.66 | 31.01 | 22.84 | -38.56 | -147.18 | 8.94 | -2.61 | 0.0045 | -- | 26.36 | 2.95 | 25.80 | -- | -1.38 | -- |
| Ourofino SA | 190.04m | 135.96m | 218.07m | 1.01k | 1.60 | 1.85 | 1.52 | 1.15 | 15.33 | 15.33 | 21.42 | 13.25 | 0.8321 | 1.68 | 3.86 | -- | 59.53 | 18.16 | 72.62 | 22.79 | 50.93 | 49.52 | 71.54 | 23.66 | 2.19 | 35.84 | 0.4107 | 14.57 | 8.64 | 10.59 | 1,729.59 | 77.46 | -3.03 | 36.23 |
| Animalcare Group Plc | 92.54m | 3.40m | 220.68m | 201.00 | 65.71 | 1.71 | 17.35 | 2.38 | 0.0426 | 0.0426 | 1.24 | 1.64 | 0.5644 | 2.79 | 5.78 | 403,343.30 | 2.08 | 1.33 | 2.42 | 1.58 | 56.36 | 55.54 | 3.68 | 2.23 | 1.27 | -- | 0.1566 | 176.02 | 4.94 | 0.858 | 339.11 | -- | 4.71 | 20.11 |
| Holder | Shares | % Held |
|---|---|---|
| Caixabank Asset Management SGIIC SAas of 22 Dec 2025 | 4.18m | 5.08% |
| Quaero Capital SAas of 30 Jun 2025 | 1.56m | 1.89% |
| Solventis SGIIC SAas of 31 Dec 2025 | 256.41k | 0.31% |
| Andbank Wealth Management SGIIC SAUas of 31 Dec 2025 | 192.87k | 0.24% |
| Quadriga Asset Managers SGIIC SAas of 31 Dec 2025 | 102.67k | 0.13% |
| UBS LA MAISON de Gestion SASUas of 31 Dec 2024 | 35.83k | 0.04% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 26.11k | 0.03% |
| GVC Gaesco Gesti�n SGIIC SAas of 31 Dec 2025 | 16.75k | 0.02% |
| Dimensional Fund Advisors Ltd.as of 30 Nov 2025 | 14.83k | 0.02% |
| Renta 4 Gestora SGIIC SAas of 31 Dec 2025 | 12.63k | 0.02% |
